Xtant Medical Holdings, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $133.9M | $117.3M | $91.3M | $58.0M | $55.3M |
| Cost of revenue | $49.7M | $49.1M | $35.8M | $25.8M | $22.8M |
| Gross profit | $84.3M | $68.2M | $55.5M | $32.1M | $32.5M |
| Research and development | $2.1M | $2.4M | $1.3M | $915,000 | $870,000 |
| Operating expenses | $77.0M | $80.3M | $65.6M | $38.9M | $36.3M |
| Operating income | $7.3M | -$12.1M | -$10.2M | -$6.8M | -$3.9M |
| Interest expense | $3.7M | $4.2M | $2.9M | $1.7M | $995,000 |
| Pretax income | $7.0M | -$16.3M | -$1.0M | -$8.4M | -$4.8M |
| Income tax expense | $2.0M | $187,000 | -$1.7M | $69,000 | — |
| Net income | $5.0M | -$16.4M | $660,000 | -$8.5M | -$4.8M |
| Balance Sheet | |||||
| Cash and equivalents | $17.1M | $6.2M | $5.7M | $20.3M | $18.2M |
| Current assets | $78.2M | $67.1M | $64.9M | $49.3M | $44.3M |
| Total assets | $94.1M | $93.8M | $92.6M | $60.2M | $54.7M |
| Current liabilities | $29.5M | $28.6M | $23.0M | $15.2M | $11.1M |
| Total liabilities | $43.2M | $50.9M | $41.3M | $26.1M | $23.8M |
| Stockholders' equity | $51.0M | $43.0M | $51.3M | $34.2M | $30.9M |
| Cash Flow Statement | |||||
| Cash from operations | $12.5M | -$11.9M | -$9.5M | -$5.3M | $439,000 |
| Depreciation and amortization | $5.2M | $4.2M | $3.2M | $1.3M | $1.3M |
| Stock-based compensation | $2.9M | $4.1M | $2.7M | $2.5M | $2.2M |
| Capital expenditure | $2.4M | $4.1M | $1.5M | $1.8M | $2.1M |
| Free cash flow | $10.2M | -$16.0M | -$11.0M | -$7.1M | -$1.7M |
Shares outstanding 140.3M · Free float 20.9%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.